VTX:ATLNActelion Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Actelion Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartHeadlines Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Actelion. Previous Next 2.0 Community Rank Outperform VotesActelion has received 95 “outperform” votes. (Add your “outperform” vote.)Underperform VotesActelion has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentActelion has received 59.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote “Outperform” if you believe ATLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldActelion does not currently pay a dividend.Dividend GrowthActelion does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actelion insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.40 out of 5 stars Industry, Sector and Symbol Stock Exchange VTX Industry N/A Sub-IndustryN/A SectorN/A Current SymbolVTX:ATLN Previous Symbol CUSIPN/A CIKN/A Webwww.actelion.com Phone+41-61-5656565Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable ATLN Rates by TradingView Receive ATLN News and Ratings via Email Sign-up to receive the latest news and ratings for ATLN and its competitors with MarketBeat's FREE daily newsletter. Actelion (VTX:ATLN) Frequently Asked Questions Has Actelion been receiving favorable news coverage? Media coverage about ATLN stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Actelion earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Actelion. Who are Actelion's key executives? Actelion's management team includes the following people: Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors (Age 69)Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors (Age 62)Thomas Widman, Co-FounderAndre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee (Age 53)Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee (Age 61)Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee (Age 60)Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee (Age 54)Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee (Age 61)Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors (Age 47)Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee (Age 52) What is Actelion's stock symbol? Actelion trades on the VTX under the ticker symbol "ATLN." What is Actelion's official website? The official website for Actelion is www.actelion.com. How can I contact Actelion? Actelion's mailing address is Gewerbestrasse 16, ALLSCHWIL, 4123, Switzerland. The company can be reached via phone at +41-61-5656565. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
